Exelixis, Inc. — Form 10-K summary
Period: The filing is for fiscal 2016, ended December 30, 2016, with comparisons to fiscal 2015 and 2014. Although the request metadata says “2015 Q4,” that does not match the filing period. The filing also presents unaudited quarterly results, including Q4 2016.
Business context and reporting period
Exelixis is an oncology-focused biopharmaceutical company. Its marketed products were CABOMETYX and COMETRIQ, both containing cabozantinib, and Cotellic (cobimetinib), commercialized with Genentech. CABOMETYX launched in the U.S. in April 2016 for previously treated advanced renal cell carcinoma (RCC); COMETRIQ is approved for medullary thyroid cancer (MTC). Exelixis operates as one reportable segment.
Key financial metrics
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Total revenue | $191.5 million | $37.2 million |
| Net product revenue | $135.4 million | $34.2 million |
| Collaboration revenue | $56.1 million | $3.0 million |
| Operating expenses | $219.6 million | $158.6 million |
| Operating loss | $28.1 million | $121.4 million |
| Net loss | $70.2 million | $161.7 million |
| Net loss per share | $0.28 | $0.77 |
| Operating cash flow | +$206.3 million | -$141.6 million |
- Revenue growth reflected the CABOMETYX U.S. launch and Ipsen collaboration payments. FY 2016 product revenue included $93.5 million from CABOMETYX and $41.9 million from COMETRIQ.
- Gross margin on product revenue was 95%, compared with 89% in 2015; the company attributed the improvement partly to CABOMETYX’s lower manufacturing cost relative to COMETRIQ.
- Research and development expense was $96.0 million, essentially unchanged from $96.4 million. Selling, general and administrative expense rose 103% to $116.1 million, mainly due to building the U.S. commercial organization for CABOMETYX.
- FY 2016 operating cash flow benefited substantially from $280 million of Ipsen upfront and milestone receipts; it should not be read as recurring operating cash generation. Investing cash flow was -$216.0 million, primarily reflecting investment purchases; financing cash flow was +$19.8 million.
- Cash and investments totaled $479.6 million at year-end, including $393.8 million available for operations, $81.6 million in compensating-balance investments and $4.2 million in long-term restricted investments. Working capital was $200.2 million.
- Year-end debt carrying value was $189.1 million: $109.1 million for Deerfield convertible notes and $80.0 million for the Silicon Valley Bank term loan. The company intended to repay Deerfield around July 2017 and owed the bank loan in May 2017. It retired the $287.5 million 2019 Notes during 2016, principally through conversion into shares, and recorded a $13.9 million extinguishment loss.
Material changes versus prior period
- Total revenue increased $154.3 million year over year; net product revenue rose 296%, largely due to the CABOMETYX launch. FY 2016 CABOMETYX sales also benefited from initial channel inventory build.
- Collaboration revenue included Ipsen-related upfront-payment amortization and milestones, as well as payments from Daiichi Sankyo and Merck. The $200 million Ipsen upfront payment and certain milestones are being recognized over the collaboration term, rather than entirely when received.
- Cash and investments increased from $253.3 million to $479.6 million. Long-term obligations fell substantially following retirement of the 2019 Notes, although debt repayments remained a near-term cash requirement.
- Common shares outstanding increased from 228.0 million to 289.9 million, including 54.0 million shares issued in the 2019 Notes conversions.
- Q4 2016 revenue was $77.6 million and net income was $35.1 million. Quarterly results included a $23.1 million recovery of previously recorded Cotellic collaboration losses; the quarter’s profit therefore included a significant unusual item.
Outlook, commentary, risks and unusual items
- Management’s 2017 priorities were to grow CABOMETYX, support COMETRIQ and Cotellic, advance cabozantinib trials, cautiously restart internal drug discovery, and evaluate licensing and acquisition opportunities. The filing provides no numerical revenue or earnings guidance.
- Management expected a 2017 supplemental filing for first-line advanced RCC based on CABOSUN phase 2 results, while noting the trial was not originally designed as a registrational study. CELESTIAL phase 3 results in previously treated advanced liver cancer were anticipated in 2017.
- Exelixis reported more than 45 ongoing or planned cabozantinib trials. It entered a clinical-trial collaboration with Bristol Myers Squibb for checkpoint-inhibitor combinations and planned a cabozantinib–atezolizumab study with Roche. These are development opportunities, not approved indications.
- In January 2017 Exelixis signed a Japan collaboration with Takeda and received a $50 million upfront payment in February 2017, after fiscal year-end.
- Genentech arbitration over Cotellic development, pricing, and cost and revenue allocations remained unresolved. Genentech withdrew its counterclaim and changed its promotional-cost allocation approach; Exelixis reported an $8.8 million net cost recovery for the year and a $23.1 million Q4 recovery of prior-period losses.
- Management highlighted dependence on CABOMETYX commercialization and clinical expansion, competition (including immunotherapies), pricing and reimbursement pressure, trial and regulatory uncertainty, reliance on partners and third-party manufacturers, and debt repayment needs. The company had a history of losses and a $2.0 billion accumulated deficit.
- The company disclosed correction of an immaterial accounting error involving the 2019 Notes’ debt discount and interest expense. Prior-period figures were revised; management said the corrections did not affect cash flows or the trend of results. The auditor issued an unqualified opinion, and management and the auditor reported effective internal control over financial reporting.
Important facts for investors to verify
- Whether CABOMETYX sales growth continued beyond the launch-period channel inventory build, and how U.S. and international demand developed.
- Whether CABOSUN supported an FDA supplemental approval and whether CELESTIAL produced favorable, statistically meaningful results.
- Actual unrestricted liquidity after the planned Deerfield repayment and the Silicon Valley Bank loan maturity, including any covenant or collateral requirements.
- How recurring product revenue and collaboration economics compare with FY 2016 cash flow, which was boosted by large Ipsen receipts.
- Resolution and financial consequences of the Genentech arbitration, and the resulting economics of Cotellic and future combinations.
- Share dilution from debt conversions, employee equity awards and any future financing; also assess the risks of competing therapies, reimbursement changes and reliance on external manufacturing and commercial partners.